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Gold in Medicine - A Brief Introduction
The serendipitous discovery of the anti-tumour activity of
cisplatin [cis-PtCI,NH32] in 1969 has led to increased in
terest in the development of new metal-based anti-cancer
drugs. However, regardless of the large numbers of new
metal-containing compounds generated, many of which
demonstrate anti-tumour activity, cisplatin still remains
one of the most widely used anti-twnour drugs in the
western world.
The similarities between goldllI and platinumII both
are d8 and fonn four-coordinate square planar complexes
give rise to the possibility of developing goldIIl ana
logues of cisplalin. The usc of gold and its compounds
in medicine is not a novel concept - ancient Arabic, In
dian and Chinese physicians used gold preparations for
the treatment of a wide variety of ailments. In 1890, Koch
demonstrated that [AuCNJ has bacteriostatic effects,
atid in the 1920's gold compounds were used for the
treatment of tuberculosis but later shown to be ineffec
tive. Today goldl thiolates, namely Myocrisin' sodium
aurothiomalate 1 and auranofin aurothioglucose 2, are
used for the treatment of rheumatoid arthritis chrysother
apy. In addition, gold complexes continue to be screened
for activity as anti-HIV, anti-microbial and anti-malarial
agents. Several comprehensive reviews are dedicated to
the medicinal applications of gold compounds and read
ers are directed towards these for a full and interesting his
tory of the topic.' A large number of gold complexes also
have been screened previously for anti-tumour activity,
the details of which can be found in selected references,24
However, despite promising results, no gold complexes
have made it into clinical use as anti-tumour agents yet,
although there continues to be a large quantity of research
devoted to the development of new gold drugs. This ar
ticle summarizes work conducted with neutral cycloau
rated complexes and details some that has been conducted
recently with goldIII complexes in our Department.
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Cycloaurated Compounds as Anti-tumour
Agents
The major set-back in the use of goldtII in medicine
is that it has a large reduction potential and is rela
tively easily reduced to goldI or gold0. This is a po
tential problem in the body because of the presence of
reducing thiol moieties, e.g. in the amino acid cysteine
I-ISCH,CHNH2CO7H. This problem seems to be largely
overcome by incorporating the gold into a metallacyclic
ring. If a chelating monoanionic ligand L is used, the
resulting complex will have the general formula LAuX,,
where X is typically a unidentate anion such as C1 ex
amples of bidentate dianionic ligands are known - see be
low. Thus, the use of these types of systems provides a
complex that remains neutral with four-coordinate square
planar geometry as is seen in cisplatin. In addition, the
presence of the chelating ligand forces the two anionic
Cl ligands into a cis arrangement that further increases
the similarity to cisplalin.
Initial studies on cycloaurated systems centred on those
containing bidentate N,O donor ligands - either salicyl
aldimine-derived Schiff bases or pyridine-2-carboxylate
as in 3 and 4, respectively. However, the results were not
promising as the complexes underwent immediate reduc
tion to elemental gold in the presence of biological media
that, presumably, was accompanied by oxidation of cel
lular material giving a disastrous toxicity.5 Later, indepen
dent studies demonstrated that these compounds did dis
play some level of cytotoxicity,' possibly from binding to
DNA,7 although other mechanisms could not be excluded
- see below.
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Most work conducted with cycloaurated organometallic
complexes has centred around dampAuC1, [5; damp =
2-IV,N-dimethylaminomethylphenyl]. As in cisplatin,
the metal atom is square-planar with two labile chloride
ligands. Additionally, goldIII is a relatively soft metal
centre so that the softer relative to N,O above C,N Ii
gand system stabilizes the metal towards reduction. Par
ish, Fricker and co-workers8'° initially investigated the
in vitro anti-tumour activity of 5 against a range of hu
man tumour cell lines and found that it was comparable
to cisplatin, a control in the experiment. Like cisplatin, 5
showed greatest toxicity against breast ZR-75- 1, blad
der HT1376 and ovarian SK-OV-3 cell lines. Because
5 showed good activity in vitro towards the breast tumour
line it was also evaluated against a solid form of the tu
mour, grown as a xenograft in nude mice. The results in
dicated that 5 possessed modest anti-tumour activity as it
reduced the size ofthe tumour, but there was also evidence
of cytotoxicity; several mice died before the conclusion of
the experiment. Overall, the results were not as promising
as the initial in vitro screening predicted, possibly because
the low solubility of the compound iii aqueous media hin
dered its transport from the injection site to the tumour.8
In light of these results, it seemed likely that analogues of
5 with enhanced aqueous solubility characteristics would
show increased activity. Replacement of the chloride
102
Chemistry in New Zealand July 2009
MeMe MeMe MeMe
,N .N -4' N o
AuX
I. 0 I
5,X=C1 7 8
6. X - OAc
ligands by acetate, malonate or oxalate groups gave com
plexes 6-8, respectively, which have better solubility. An
addcd attractive feature of the acetato 6 is that, like cispla
tin, the two labile ligands are hydrolysed in aqueous solu
tions.9 Thus, 5-8 were evaluated in vitro against a panel of
human solid tumours and, consequently, the bladder car
cinoma HTI 376 was consistently the most sensitive to
the new goldIJl complexes. In a similar manner to that
described above, the complexes were evaluated in vivo
against a bladder cell HT1376 xenograft. Diacetato-6
and malonato-7 complexes showed activity similar to that
of ci3platin; dichioride precursorS showed reduced activ
ity and the oxalato derivative 8 was inactive, again pos
sibly because of reduced solubility. In addition, acetato-6
was also found to be active against the cisplatin-sensitive
PXNII 09/TC tumour albeit less so.'°
As goldIII is considerably more labile than platinumlI,
it was suggested that compounds containing ligands bound
fairly tightly to the gold centre may exhibit cnhanced ac
tivity.'1 Therefore, Henderson and co-workers synthesized
a range of bis-metallacyclic compounds that, in addition
to the original damp metallacycle, contained a second
metallacyclic ring produced upon substitution of the two
chloride ligands with dianionic thiosalicylate,'2 salicy
late,'2 aurathietane dioxide,' ureylene,'3 catecholate'4 or
amidate'5 ligands. The anti-tumour activity was evaluated
in vitro against the P388 murine leukemia cell line and the
results are presented in Table I. The activity is reported as
an IC50 value, which is the concentration tM required
to reduce the cell growth by 50%; smaller concentrations
equate to a higher activity. In particular, thiosalicylate-lO
and catecholate-14 show good anti-tumour activity, and
derivatives containing these ligands could benefit from
further study. In addition, the complexes cariying a me
thoxy substituent on the phenyl ring of the damp ligand
show better activity than their unsubstituted analogues, cf
10 vs 9; this is possibly because of increased solubility.
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Table 1. The anti-tumour activity P388 of selected gold111
metallacycles
JC0 jiM ICtM
9 4.01 14 0.46
10 0.59 15 14.5
11 10.2 16 6.68
12 0.70 17 1.09
13 12.9
Other cycloaurated complexes that have been evaluated
for anti-tumour activity in vitro are 18-22. These contain
the related C,Nco-ordinatecl 2-phenylpyridine ligand. The
activity against MOLT-4 human leukemia and C2C12
mouse tumour cell lines indicated that the gold com
plexes were more active than cisplatin against the MOLT-
4 cell line. However, with the exception of 22 they were
inactive towards the C2C12 cell line.'0 GoldIII com
plexes that contain monoanionic N,N'-chelating ligands,
e.g. picolinamide 23, or two bridging pyrazolide ions 24
and 25 have also been evaluated against the MOLT-4 and
C2C12 cell lines; the results indicate that the complexes
have activity comparable to cLsplarin.'7
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Mechanistic Considerations
It is well established that the molecular target of cisplatin
is DNA. After in vivo hydrolysis of the chloride ligands
to form a species such as [PtClNH32H,O], the com
plex binds to adjacent nitrogen atoms N-7 of guanine
residues forming intra-strand crosslinks. Hydrogen bond
ing between cisplatin and phosphate groups on the DNA
backbone may aid the interactions. It seems unlikely that
the goldIIl complexes will interact with DNA in the
same fashion as some show activity against cisplatin re
sistant cell lines. In a series of experiments, it was shown
that reaction of the damp acetate-6 with N-donor nucleo
sides, such as guanosine, gave non-quantitative binding
and, in addition, the coordination was to alternative ni
trogen atoms, viz, not N-7. Later, a series of detailed ex
periments conducted by Parish and Fricker also with 6
demonstrated that this complex, and by inference other
damp analogues, reacts by way of a different mechanism
from that for cisplatin, and that DNA may not be the tar
get molecule.'°
An alternative molecular target for goldlII complexes
may be cathepsin B, a cysteine protease that is implicated
in the pathophysiology of a variety of diseases including
cancer. Although the exact role of cathepsin B in solid
tumours is not fully known, it is thought to be involved
18,X-C1 21
19, X = OAc
20, X = PNCO,
21
15 16 T-MeeH4 17
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in tumour metathesis, angiogenesis, and tumour progres
sion. As gold drugs are known to react with thiols, the
interaction of gold1ll complexes with cathepsiri B was
investigated and. indeed, the goldlII damp complexes
- and related six-membered ring analogues - were shown
to be moderate inhibitors of the enzyme. Binding of the
gold complexes to the enzyme was tight, but i-eversible
and this is preferable in a drug candidate. Recently, it has
been proposed that goldIII complexes have anti-micro
bial effects, possibly by inhibiting the enzyme thioredoxin
reductase.3
Current Research at Waikato
We have become interested in developing new metallacy
clic systems that contain a gold1II metal centre because
of the promising anti-tumour activity displayed by cer
tain of the goldIIl complexes described above. We have
prepared a series of new compounds and subjected them
to preliminary in-vitro screening against the P388 murine
leukemia cell line.
cydoaurated Phosphorimine Systems
Phosphorimines are ligands that, like damp, coordinate to
the gold centre through carbon and nitrogen. Because of
the similarity of these complexes to the damp systems de
scribed above, a selection of goldII1 iminophosphorane
complexes, along with their thiosalicylate and catecholate
derivatives, were screened for anti-tumour activity against
the P388 nmrine leukemia cell line.''9 The results appear
in Table 2.
Table 2. The anti-tumour activity P388 of selected goldIII
iminophosphoranes
1C itM lC tM
26 10.7 29 0.97
27 33.4 30 <0.74
28 <0.69 31 1.03
R
PhpN
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27, R = BLI' 29. R = Bu' 31. R Bu'
The series of complexes that contain a phenyl substituted
iminophosphorane ligand. namely 26, 28 and 30, are con
sistently more active than the analogues 27, 29 and 31 that
carry a I-Bu substituent. In addition, the thiosalicylate or
catecholate derivatives 28-31 show a cci. ten-fold increase
in activity over the dichloride precursors. The IC50 val
ties of 30 <0.74 1tM and 28 <0.69 ILM are comparable
to the analogous damp complexes 14 0.46 pM and 10
0.59 hiM, respectively. This indicates that changing the
cycloaurated precursor and introducing a phosphorus into
the metallacyclic ring, whilst slightly altering the elec
tronic and steric properties, does not significantly change
the activity of the complexes.
cycloairated Ph osplzine Sulfide Systems
Complexes 32-34 are a unique class of cycloaurated com
plexes in that the neutral donor ligand is not nitrogen; they
also contain a ligand coordinated to the gold centre that
is potentially reducing, These complexes were screened
to see if changing the neutral donor ligand had any sig
nificant effect on the anti-tumour activity. Compound 32,
which contains a cycloaurated triphenyiphosphine sulfide
moiety, is essentially inactive against the P388 murine leu
kemia cell line lC0 >22 pM. Compound 33, in which the
two free phenyl rings of 32 are replaced by NEt, groups,
was much more active 1C50 6.31 pM, possibly because
of increased solubility. As with the above, thiosalicylate
34 again is somewhat more active IC} = 2.4 pM9
PJAuCI2 Et2N3AucI2 Et2cAu
cycloanrated Pyridylsulfonainide Systems
The N,N-coordinated system no longer contains a carbon-
gold ci bond but instead a ci pyridylnitrogen-gold bond,
analogous to cycloaurated picolinamide 23. Although 23
had promising activity against MOLT-4 and C2C12 cell
lines, the anti-tumour activity of complexes 35-39 was
poor as all had IC50 values > 22 pM. These complexes
are not as stable as the C,N counterparts as they undergo
reduction with mild reducing agents such as phosphines;
this may well be a factor in the poor biological activity of
these complexes.2°
O,S
J "uci, . .AUCI,N
35, R1o1
36, R=Ph
37, R'N1e
Concluding Remarks
The structural similarities between goldII1 and
platinurn1I suggest that there is a possibility to develop
gold analogues ofthe prominent anti-cancer drug cisplatin.
Despite promising results from early prelirninaiy screen
ings, no gold drugs have made it into clinical use. The
gold1II complexes synthesized in our laboratories con
tain a carbon-gold bond and show promising anti-tumour
activity against the P388 murine leukemia cell line. This
is especially so when the dichloride ligands are replaced
with chelating dianionic ligands such as thiosalicylate or
catecholate. In addition, the iminophosphorane ligand is
easily tuned to increase desirable properties in the final
complex, and work is currently underway to investigate
more water soluble derivatives. Further studies on these
compounds, especially the more water soluble variants
and their thiosalicylate and catecholate derivatives, will
include testing against other cell lines. When the neutral
donor ligand is changed from nitrogen to sulphur the ac
tivity decreases and if the complexes contain no carbon-
gold bond, e.g. with N,N cycloaurated ligands, complete
inactivity is recorded.
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